ライフサイエンスコーパス: opicapone

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 all patients received active treatment with opicapone.

2 110 in the opicapone 5 mg group, 105 in the opicapone 25 mg group, and 106 in the opicapone 50 mg gr

3 119 in the opicapone 5 mg group, 116 in the opicapone 25 mg group, and 115 in the opicapone 50 mg gr

4 17 in the opicapone 5 mg group, nine in the opicapone 25 mg group, and 18 in the opicapone 50 mg gro

5 opicapone 5 mg group, 65 (55%) of 119 in the opicapone 25 mg group, and 62 (54%) of 115 in the opicap

6 g and opicapone 50 mg groups, and one in the opicapone 25 mg group.

7 5 mg, -85.9 min (13.7; -112.8 to -59.1) for opicapone 25 mg, and -116.8 min (14.0; -144.2 to -89.4)

8 Treatment with opicapone 5 mg (p=0.056) or 25 mg (p=0.080) was not sign

9 ht in the entacapone group, four each in the opicapone 5 mg and opicapone 50 mg groups, and one in th

10 oup, 104 in the entacapone group, 110 in the opicapone 5 mg group, 105 in the opicapone 25 mg group,

11 oup, 120 in the entacapone group, 119 in the opicapone 5 mg group, 116 in the opicapone 25 mg group,

12 the entacapone group, 63 (52%) of 122 in the opicapone 5 mg group, 65 (55%) of 119 in the opicapone 2

13 roup, ten in the entacapone group, 17 in the opicapone 5 mg group, nine in the opicapone 25 mg group,

14 apone, -91.3 min (13.5; -117.7 to -64.8) for opicapone 5 mg, -85.9 min (13.7; -112.8 to -59.1) for op

15 er-generated sequence to oral treatment with opicapone (5 mg, 25 mg, or 50 mg once daily), placebo, o

16 in the opicapone 25 mg group, and 115 in the opicapone 50 mg group) and 537 in the per-protocol set (

17 in the opicapone 25 mg group, and 18 in the opicapone 50 mg group), insomnia (in one, seven, two, se

18 in the opicapone 25 mg group, and 106 in the opicapone 50 mg group).

19 pone 25 mg group, and 62 (54%) of 115 in the opicapone 50 mg group.

20 e group, four each in the opicapone 5 mg and opicapone 50 mg groups, and one in the opicapone 25 mg g

21 The addition of opicapone 50 mg to levodopa treatment in patients with P

22 Treatment with opicapone 50 mg was superior to placebo (mean difference

23 , and -116.8 min (14.0; -144.2 to -89.4) for opicapone 50 mg.

24 e aimed to assess the safety and efficacy of opicapone as an adjunct to levodopa compared with placeb

25 bo-controlled and active-controlled trial of opicapone as an adjunct to levodopa in patients with Par

26 acy and safety of 25- and 50-mg/d dosages of opicapone compared with placebo as adjunct to levodopa t

27 s followed a hierarchical procedure for each opicapone dose in which superiority compared with placeb

28 minutes; P = .008), but not for the 25-mg/d opicapone group (treatment effect, -37.2 [95% CI, -80.8

29 e vs placebo was significant for the 50-mg/d opicapone group (treatment effect, -54.3 [95% CI, -96.2

30 group, -101.7 (14.9) minutes for the 25-mg/d opicapone group, and -118.8 (13.8) minutes for the 50-mg

31 p, and -118.8 (13.8) minutes for the 50-mg/d opicapone group.

32 tudy evaluated a 25- and a 50-mg/d dosage of opicapone in a randomized, double-blind, 14- to 15-week,

33 Opicapone is a novel, once-daily, potent third-generatio

34 The most common adverse events in the opicapone vs placebo groups were dyskinesia, constipatio

35 Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in

36 Opicapone was designed to be effective without the adver

37 Opicapone was safe and well tolerated.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。